These findings provide novel insights into the prevention and screening of pathogenic genes in heritable cardiomyopathy and suggest that targeting the MQC system might confer new therapeutic benefits on FARS2 (mitochondrial phenylalanyl-tRNA synthetase)–associated cardiomyopathy. Here, FARS2 is linked to cardiomyopathy.